Anatara Lifesciences Ltd (AU:ANR) has released an update.
Anatara Lifesciences Ltd has successfully secured A$1.0 million in funding through a placement to existing institutional and sophisticated investors, with shares priced at a slight discount to recent averages. The capital will be used to refine their GaRP product for IBS treatment, prepare for commercial manufacturing, and strengthen the company’s balance sheet for potential licensing deals. The ongoing Phase II GaRP-IBS trial has shown promising results, and further updates on the trial’s progress are expected in the upcoming quarter.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.
